Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma

Sanofi has licensed Kiadis’s modified K-NK cell therapies to combine with its anti-CD38 antibody Sarclissa in multiple myeloma. How could this combination approach improve treatment outcomes for these blood cancer patients?

Close
Close
Close

Go Top